Jiangxi Dadi Pharmaceutical Co., Ltd. has recently announced several new projects which are currently underway. These projects focus on the production of several important raw materials for pharmaceuticals and animal medicine.
One notable project is the 500 ton/year Norfloxacin API (active pharmaceutical ingredient) technical transformation project. With a total investment of 80 million RMB ($12.5 million USD), this project is being carried out at the company's existing facility in Jiangxi. The project will create a new Norfloxacin production line and warehouse, as well as related facilities such as water and electricity supply and environmental protection measures. Once completed, the project will have an annual output of 500 tons of Norfloxacin API.
In conclusion, Jiangxi Dadi Pharmaceutical Co., Ltd. is investing heavily in the production of important raw materials for pharmaceutical and animal medicine. These projects represent significant advancements in the field of pharmaceutical manufacturing and demonstrate the company's commitment to improving healthcare through innovation and investment in research and development